In LT recipients diagnosed with HCC beyond the Milan Criteria, those with high USP22 expression presented a lower 3‐year overall survival (OS) rate than those with low USP22 expression (74.8% vs. This evidence concerns the gene USP22 and hepatocellular carcinoma.